Cargando…
OA04-01. Safety and immunogenicity of LIPO-5, a HIV-1 lipopeptide vaccine: results of ANRS VAC18, a phase 2, randomized, double-blind, placebo-controlled trial
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2009
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767546/ http://dx.doi.org/10.1186/1742-4690-6-S3-O25 |
| _version_ | 1782173319269711872 |
|---|---|
| author | Salmon-Céron, D Durier, C Desaint, C Cuzin Surenaud, M Hénin, Y Lelièvre, J Bonnet, B Pialoux, G Poizot-Martin, I Ben Hamouda, N Jackson, A Flys, C Guérin, C Aboulker, J Choppin, J Launay, O |
| author_facet | Salmon-Céron, D Durier, C Desaint, C Cuzin Surenaud, M Hénin, Y Lelièvre, J Bonnet, B Pialoux, G Poizot-Martin, I Ben Hamouda, N Jackson, A Flys, C Guérin, C Aboulker, J Choppin, J Launay, O |
| author_sort | Salmon-Céron, D |
| collection | PubMed |
| description | |
| format | Text |
| id | pubmed-2767546 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2009 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-27675462009-10-28 OA04-01. Safety and immunogenicity of LIPO-5, a HIV-1 lipopeptide vaccine: results of ANRS VAC18, a phase 2, randomized, double-blind, placebo-controlled trial Salmon-Céron, D Durier, C Desaint, C Cuzin Surenaud, M Hénin, Y Lelièvre, J Bonnet, B Pialoux, G Poizot-Martin, I Ben Hamouda, N Jackson, A Flys, C Guérin, C Aboulker, J Choppin, J Launay, O Retrovirology Oral Presentation BioMed Central 2009-10-22 /pmc/articles/PMC2767546/ http://dx.doi.org/10.1186/1742-4690-6-S3-O25 Text en Copyright © 2009 Salmon-Céron et al; licensee BioMed Central Ltd. |
| spellingShingle | Oral Presentation Salmon-Céron, D Durier, C Desaint, C Cuzin Surenaud, M Hénin, Y Lelièvre, J Bonnet, B Pialoux, G Poizot-Martin, I Ben Hamouda, N Jackson, A Flys, C Guérin, C Aboulker, J Choppin, J Launay, O OA04-01. Safety and immunogenicity of LIPO-5, a HIV-1 lipopeptide vaccine: results of ANRS VAC18, a phase 2, randomized, double-blind, placebo-controlled trial |
| title | OA04-01. Safety and immunogenicity of LIPO-5, a HIV-1 lipopeptide vaccine: results of ANRS VAC18, a phase 2, randomized, double-blind, placebo-controlled trial |
| title_full | OA04-01. Safety and immunogenicity of LIPO-5, a HIV-1 lipopeptide vaccine: results of ANRS VAC18, a phase 2, randomized, double-blind, placebo-controlled trial |
| title_fullStr | OA04-01. Safety and immunogenicity of LIPO-5, a HIV-1 lipopeptide vaccine: results of ANRS VAC18, a phase 2, randomized, double-blind, placebo-controlled trial |
| title_full_unstemmed | OA04-01. Safety and immunogenicity of LIPO-5, a HIV-1 lipopeptide vaccine: results of ANRS VAC18, a phase 2, randomized, double-blind, placebo-controlled trial |
| title_short | OA04-01. Safety and immunogenicity of LIPO-5, a HIV-1 lipopeptide vaccine: results of ANRS VAC18, a phase 2, randomized, double-blind, placebo-controlled trial |
| title_sort | oa04-01. safety and immunogenicity of lipo-5, a hiv-1 lipopeptide vaccine: results of anrs vac18, a phase 2, randomized, double-blind, placebo-controlled trial |
| topic | Oral Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767546/ http://dx.doi.org/10.1186/1742-4690-6-S3-O25 |
| work_keys_str_mv | AT salmoncerond oa0401safetyandimmunogenicityoflipo5ahiv1lipopeptidevaccineresultsofanrsvac18aphase2randomizeddoubleblindplacebocontrolledtrial AT durierc oa0401safetyandimmunogenicityoflipo5ahiv1lipopeptidevaccineresultsofanrsvac18aphase2randomizeddoubleblindplacebocontrolledtrial AT desaintc oa0401safetyandimmunogenicityoflipo5ahiv1lipopeptidevaccineresultsofanrsvac18aphase2randomizeddoubleblindplacebocontrolledtrial AT cuzin oa0401safetyandimmunogenicityoflipo5ahiv1lipopeptidevaccineresultsofanrsvac18aphase2randomizeddoubleblindplacebocontrolledtrial AT surenaudm oa0401safetyandimmunogenicityoflipo5ahiv1lipopeptidevaccineresultsofanrsvac18aphase2randomizeddoubleblindplacebocontrolledtrial AT heniny oa0401safetyandimmunogenicityoflipo5ahiv1lipopeptidevaccineresultsofanrsvac18aphase2randomizeddoubleblindplacebocontrolledtrial AT lelievrej oa0401safetyandimmunogenicityoflipo5ahiv1lipopeptidevaccineresultsofanrsvac18aphase2randomizeddoubleblindplacebocontrolledtrial AT bonnetb oa0401safetyandimmunogenicityoflipo5ahiv1lipopeptidevaccineresultsofanrsvac18aphase2randomizeddoubleblindplacebocontrolledtrial AT pialouxg oa0401safetyandimmunogenicityoflipo5ahiv1lipopeptidevaccineresultsofanrsvac18aphase2randomizeddoubleblindplacebocontrolledtrial AT poizotmartini oa0401safetyandimmunogenicityoflipo5ahiv1lipopeptidevaccineresultsofanrsvac18aphase2randomizeddoubleblindplacebocontrolledtrial AT benhamoudan oa0401safetyandimmunogenicityoflipo5ahiv1lipopeptidevaccineresultsofanrsvac18aphase2randomizeddoubleblindplacebocontrolledtrial AT jacksona oa0401safetyandimmunogenicityoflipo5ahiv1lipopeptidevaccineresultsofanrsvac18aphase2randomizeddoubleblindplacebocontrolledtrial AT flysc oa0401safetyandimmunogenicityoflipo5ahiv1lipopeptidevaccineresultsofanrsvac18aphase2randomizeddoubleblindplacebocontrolledtrial AT guerinc oa0401safetyandimmunogenicityoflipo5ahiv1lipopeptidevaccineresultsofanrsvac18aphase2randomizeddoubleblindplacebocontrolledtrial AT aboulkerj oa0401safetyandimmunogenicityoflipo5ahiv1lipopeptidevaccineresultsofanrsvac18aphase2randomizeddoubleblindplacebocontrolledtrial AT choppinj oa0401safetyandimmunogenicityoflipo5ahiv1lipopeptidevaccineresultsofanrsvac18aphase2randomizeddoubleblindplacebocontrolledtrial AT launayo oa0401safetyandimmunogenicityoflipo5ahiv1lipopeptidevaccineresultsofanrsvac18aphase2randomizeddoubleblindplacebocontrolledtrial |